1. Phylogeny  
Ephrin type-A receptor 7 (EPHA7), also known as EHK3 or HEK11, is a member of the Eph receptor family of receptor tyrosine kinases that arose early in metazoan evolution. Comparative integromics analyses reveal that orthologs of EPHA7 are conserved among vertebrates, with well‐conserved promoter elements and domain architectures observed in primates, bovines, and other species (katoh2006comparativeintegromicson pages 1-2, katoh2006comparativeintegromicson pages 2-4). Within the human kinome, EPHA7 is grouped into the EphA subclass, which is characterized by preferential binding to glycosylphosphatidylinositol-anchored ephrin-A ligands rather than the transmembrane ephrin-B ligands found in the EphB subclass (barquilla2015ephreceptorsand pages 1-3, lackmann2008ephaprotein pages 2-3). Phylogenetic reconstructions using Bayesian and maximum likelihood methods consistently place EPHA7 in a monophyletic cluster with other EphA receptors, such as EPHA8 and EPHA10, suggesting that gene duplication events early in vertebrate evolution led to the expansion and functional diversification of the EphA subgroup (katoh2006comparativeintegromicson pages 2-4, arcas2020theevolutionaryhistory pages 1-2). In addition, the conservation of key promoter motifs—including TCF/LEF-binding sites among orthologs in human, chimpanzee, and cow—underscores the evolutionary conservation not only of the protein’s structure but also its regulation (katoh2006comparativeintegromicson pages 2-4). Thus, EPHA7 is phylogenetically assigned to the EphA receptor family, with its orthologs maintained across vertebrate species and its evolutionary relationships defined by conserved extracellular and catalytic domains that are critical for cell–cell signaling (anderton2021theroleof pages 2-4, arcas2020theevolutionaryhistory pages 2-3).

2. Reaction Catalyzed  
EPHA7 functions as a receptor tyrosine kinase that catalyzes the transfer of a phosphate group from ATP to tyrosine residues on protein substrates. The chemical reaction can be summarized by the equation:  
  ATP + [protein]-tyrosine → ADP + [protein]-phosphotyrosine + H⁺  
This phosphorylation reaction is initiated by ligand binding, which promotes receptor dimerization or oligomerization and triggers autophosphorylation of key tyrosine residues within the intracellular kinase domain (barquilla2015ephreceptorsand pages 1-3). Autophosphorylation not only activates the receptor’s catalytic function but also creates docking sites for SH2 domain–containing downstream signaling proteins that propagate the forward signaling cascade (anderton2021theroleof pages 2-4).

3. Cofactor Requirements  
The catalytic activity of EPHA7 depends on the presence of divalent metal ions, with Mg²⁺ serving as the essential cofactor. Magnesium ions are required to coordinate the binding of ATP within the active site of the kinase domain, ensuring the correct orientation for efficient phosphate transfer to substrate tyrosine residues (barquilla2015ephreceptorsand pages 1-3, kwon2019tracingtheevolution pages 69-74). While other divalent cations such as Mn²⁺ might occasionally support kinase activity, Mg²⁺ is the predominant cofactor necessary for optimal EPHA7 function.

4. Substrate Specificity  
EPHA7 exhibits substrate specificity characteristic of receptor tyrosine kinases. Upon activation, the receptor autophosphorylates specific tyrosine residues within its intracellular domain, generating binding sites for downstream signaling molecules that contain SH2 domains. Although a definitive consensus substrate motif for EPHA7 has not been rigorously established in the literature, its catalytic activity is primarily directed toward tyrosine residues present in a subset of intracellular proteins that regulate cytoskeletal dynamics and cell adhesion (barquilla2015ephreceptorsand pages 1-3). Studies of Eph receptors in general have emphasized that the precise substrate specificity is often context dependent and may involve sequence motifs that favor phosphorylation when the receptor is part of multiprotein complexes (anderton2021theroleof pages 2-4). The phosphorylation events triggered by EPHA7 are critical for activating downstream signaling cascades, including components of the ERK pathway, which in turn affect cellular processes such as migration and proliferation. In summary, the substrate specificity of EPHA7 centers on the phosphorylation of tyrosine residues within both autophosphorylation sites on the receptor itself and on associated adaptor proteins that orchestrate cell–cell communication.

5. Structure  
EPHA7 displays a modular domain organization typical of the Eph receptor family. Its structure comprises three primary regions: an extracellular segment, a single-pass transmembrane helix, and an intracellular cytoplasmic portion.  
  • The extracellular region features a compact ligand-binding domain at the N-terminus that is necessary and sufficient for high-affinity binding to GPI-anchored ephrin-A ligands, such as EFNA5. This domain is followed by a cysteine-rich region and two fibronectin type III (FNIII) repeats that contribute to ligand specificity and receptor clustering (barquilla2015ephreceptorsand pages 1-3, chatzikalil2024theclinicalrelevance pages 1-2).  
  • The transmembrane domain anchors EPHA7 in the plasma membrane and supports the transmission of extracellular ligand-binding events to the intracellular catalytic machinery.  
  • The intracellular portion contains a highly conserved protein tyrosine kinase domain arranged in the canonical bilobed structure. The N-terminal lobe binds ATP, and the C-terminal lobe is responsible for substrate recognition and catalysis. Key structural features within the kinase domain include the activation loop—whose conformation is altered upon autophosphorylation—the αC helix, and a hydrophobic spine that stabilizes the active conformation (bajaj2023crystalstructureof pages 8-11). Additionally, a sterile alpha motif (SAM) domain is present downstream of the kinase domain; this domain is implicated in mediating receptor clustering and interactions with other proteins, though its precise functional contribution in EPHA7 signaling remains less clear (vearing2005structurefunctionand pages 42-45). A PDZ-binding motif at the extreme C-terminus further enables interactions with intracellular scaffold proteins and contributes to the formation of signaling complexes (barquilla2015ephreceptorsand pages 29-30, vearing2005structurefunctionand pages 45-48).  
High-resolution structural studies, including X-ray crystallography and AlphaFold-predicted models, have confirmed that the Eph receptor kinase domain adopts a two-lobed structure, with features such as the DFG motif, HRD motif, and a regulatory juxtamembrane segment that undergoes autophosphorylation. Comparative structural analysis shows that the kinase domain of choanoflagellate RTKC8 is highly similar to that of metazoan Eph receptors, underscoring a deep evolutionary conservation of the catalytic fold (bajaj2023crystalstructureof pages 8-11). Together, these structural elements define the molecular framework that underpins EPHA7’s ligand-binding capacity, catalytic activity, and interactions with downstream signaling partners.

6. Regulation  
The regulation of EPHA7 is achieved through a combination of extracellular ligand binding, receptor clustering, and a series of post-translational modifications. Ligand engagement by ephrin-A ligands, particularly EFNA5, initiates the process by inducing receptor dimerization or oligomerization. This clustering is essential for relieving the autoinhibitory conformation maintained by the juxtamembrane region and for promoting autophosphorylation within the kinase domain (barquilla2015ephreceptorsand pages 1-3, vearing2005structurefunctionand pages 45-48). Autophosphorylation of specific tyrosine residues not only enhances the catalytic activity of EPHA7 but also generates phosphotyrosine docking sites for SH2 domain-containing proteins, facilitating the assembly of signaling complexes.  
In addition to autophosphorylation, regulatory control is exerted via receptor endocytosis and ectodomain shedding. Ligand-induced proteolytic cleavage by metalloproteases can release a soluble fragment of EPHA7, thereby modulating the availability of the full-length receptor at the cell surface (barquilla2015ephreceptorsand pages 17-19). This process, together with ubiquitination and subsequent lysosomal targeting, contributes to the termination of EPHA7 signaling and prevents sustained receptor activation (vearing2005structurefunctionand pages 51-55).  
Furthermore, cross-talk with intracellular signaling pathways adds an additional layer of regulation. Activation of EPHA7 is known to stimulate downstream phosphorylation events in the ERK pathway; specifically, the activated receptor leads to the phosphorylation of MAP2K1, MAP2K2, MAPK1, and MAPK3, thereby integrating EPHA7 signaling with broader cellular responses such as proliferation and differentiation (barquilla2015ephreceptorsand pages 1-3, chatzikalil2024theclinicalrelevance pages 1-2).  
MicroRNA-mediated regulation has also been reported in the context of EPHA7. For example, miR-137 has been shown to target EPHA7 in endothelial cells, leading to alterations in receptor expression and affecting cell migration (lu2014mir137regulatesthe pages 6-6). This post-transcriptional control mechanism further fine-tunes the receptor’s activity in specific cellular contexts.  
Together, these regulatory mechanisms—including ligand-triggered receptor clustering, autophosphorylation, proteolytic processing, and microRNA-mediated modulation—ensure that EPHA7 signaling remains tightly controlled during both development and in adult tissues.

7. Function  
EPHA7 plays multiple roles in mediating cell–cell communication and is essential for various developmental and physiological processes. In the nervous system, EPHA7 is critically involved in axon guidance and the topographic mapping of neuronal projections. By binding to ephrin-A ligands on neighboring cells, EPHA7 mediates repulsive signaling that directs the trajectory of axons in developing brain regions. For instance, it is pivotal in guiding corticothalamic axons and in ensuring the precise mapping of retinal axons to the superior colliculus, thereby contributing to the proper formation of visual and somatosensory neural circuits (barquilla2015ephreceptorsand pages 1-3, kim2016epha7regulatesspiral pages 18-18).  
Another key function of EPHA7 is its participation in modulating cell adhesion and migration. Activation of EPHA7 triggers forward signaling pathways that result in the phosphorylation of downstream effectors—including components of the ERK signaling cascade such as MAP2K1, MAP2K2, MAPK1, and MAPK3—which ultimately influence cytoskeletal dynamics and cell motility (barquilla2015ephreceptorsand pages 1-3, anderton2021theroleof pages 12-13). This regulation is of paramount importance during embryogenesis, where coordinated cell movement and proper tissue patterning are required for organogenesis.  
Beyond neural development, EPHA7 is expressed in tissues relevant to vascular development. Although its role in angiogenesis is not as extensively characterized as that of certain other Eph receptors, evidence suggests that EPHA7 may contribute to endothelial cell assembly and the regulation of vascular patterning. This function is further supported by findings that link EPHA7 expression to microRNA-mediated control in endothelial cells, thereby affecting cell migration and potentially vascular remodeling (lu2014mir137regulatesthe pages 6-6, chatzikalil2024theclinicalrelevance pages 2-4).  
EPHA7 also plays a role in cell survival and programmed cell death. Its signaling has been associated with a caspase-3-dependent proapoptotic activity that may be important during brain development by eliminating supernumerary or misplaced neurons, and thus refining neural circuitry (barquilla2015ephreceptorsand pages 1-3). The dual nature of Eph receptor signaling allows EPHA7 to function in both promoting cell survival in some contexts while inducing apoptosis in others, depending on the cellular environment and the specific complement of interacting partners.  
In the context of cancer, the function of EPHA7 has been observed to be highly context dependent. In certain tumor types, alterations in EPHA7 expression—whether through genetic mutations or epigenetic modifications such as promoter methylation—have been correlated with tumor progression and aggressiveness. For example, studies in pediatric solid tumors indicate that reduced expression of EPHA7 is associated with poor prognosis, suggesting a potential tumor-suppressive role (barquilla2015ephreceptorsand pages 17-19, chatzikalil2024theclinicalrelevance pages 22-23). At the same time, in other contexts, aberrant signaling through Eph receptors may contribute to oncogenic processes by enhancing cell survival, migration, and invasiveness (anderton2021theroleof pages 13-15).  
Moreover, EPHA7 is involved in the integration of multiple signaling pathways. Its activation leads to the recruitment of various adaptor proteins that connect its kinase activity to downstream effectors involved in cytoskeletal reorganization and cell adhesion. These interactions are essential for maintaining tissue architecture and enabling dynamic responses during developmental processes, such as the segregation of cell populations and the formation of morphogenetic boundaries (barquilla2015ephreceptorsand pages 1-3, lackmann2008ephaprotein pages 13-14).  
Collectively, the functional roles of EPHA7 encompass its activities in neural circuit formation, cell adhesion and migration, vascular development, apoptosis, and, in some instances, cancer pathobiology. Its ability to engage in bidirectional signaling—mediating both forward signaling in the receptor-expressing cell and reverse signaling in the ephrin-expressing cell—underscores its importance as a mediator of contact-dependent intercellular communication during development and disease.

8. Other Comments  
EPHA7, with its alternative names EHK3 and HEK11, is recognized as a multifunctional receptor whose regulatory complexity makes it an attractive target for therapeutic intervention. Although no EPHA7-specific inhibitors have been validated in clinical studies to date, strategies aimed at modulating Eph receptor interactions, such as the use of monoclonal antibodies, soluble receptor fragments, or RNA interference, are under active investigation (barquilla2015ephreceptorsand pages 17-19, chatzikalil2024theclinicalrelevance pages 22-23).  
In addition to its signaling role, EPHA7 is of interest because of its dual functionality: while its forward signaling is essential for guiding neuronal connections and regulating cell adhesion, its activation can also trigger caspase-dependent apoptotic pathways that are critical during brain development. This capacity for inducing apoptosis has significant implications for understanding neurodevelopmental disorders, even though detailed mutation analyses specific to EPHA7 remain sparse in the literature (barquilla2015ephreceptorsand pages 1-3).  
Furthermore, epigenetic regulation plays an important role in dictating the expression levels of EPHA7. Promoter methylation and microRNA targeting (e.g., by miR-137) have been reported to modulate its expression in various tissues, particularly in endothelial cells and tumor contexts. Such regulatory mechanisms are thought to contribute to the observed dichotomy in Eph receptor function, where EPHA7 may act as either a tumor suppressor or an oncogene depending on the cellular milieu (lu2014mir137regulatesthe pages 6-6, chatzikalil2024theclinicalrelevance pages 22-23).  
The evolutionary conservation of EPHA7’s domain architecture not only emphasizes its fundamental role in intercellular signaling but also provides a robust basis for the development of targeted therapeutics aimed at modulating its activity. Inhibitor development within the Eph receptor family is complicated by the promiscuous nature of receptor–ligand interactions and the context-dependent outcomes of signaling. Nonetheless, continued research into the structural and functional nuances of EPHA7 is expected to yield novel approaches for therapeutic intervention in diseases where its signaling is aberrant, including certain cancers and neurodevelopmental disorders (anderton2021theroleof pages 12-13, katoh2006comparativeintegromicson pages 2-4).  
Overall, EPHA7 is a critical mediator of cell–cell communication that integrates a complex array of regulatory signals through its conserved extracellular, transmembrane, and intracellular domains. Its multifaceted roles across neuronal development, vascular patterning, and cancer biology underscore its importance as a therapeutic target, while its evolutionary conservation among vertebrates highlights its fundamental contribution to the orchestration of developmental processes.

References

1. (barquilla2015ephreceptorsand pages 1-3): Antonio Barquilla and Elena B. Pasquale. Eph receptors and ephrins: therapeutic opportunities. Annual Review of Pharmacology and Toxicology, 55:465-487, Jan 2015. URL: https://doi.org/10.1146/annurev-pharmtox-011112-140226, doi:10.1146/annurev-pharmtox-011112-140226. This article has 339 citations and is from a highest quality peer-reviewed journal.

2. (katoh2006comparativeintegromicson pages 1-2): Masuko Katoh and Masaru Katoh. Comparative integromics on eph family. International Journal of Oncology, May 2006. URL: https://doi.org/10.3892/ijo.28.5.1243, doi:10.3892/ijo.28.5.1243. This article has 33 citations and is from a peer-reviewed journal.

3. (katoh2006comparativeintegromicson pages 2-4): Masuko Katoh and Masaru Katoh. Comparative integromics on eph family. International Journal of Oncology, May 2006. URL: https://doi.org/10.3892/ijo.28.5.1243, doi:10.3892/ijo.28.5.1243. This article has 33 citations and is from a peer-reviewed journal.

4. (anderton2021theroleof pages 13-15): Meg Anderton, Emma van der Meulen, Melissa J. Blumenthal, and Georgia Schäfer. The role of the eph receptor family in tumorigenesis. Cancers, 13:206, Jan 2021. URL: https://doi.org/10.3390/cancers13020206, doi:10.3390/cancers13020206. This article has 67 citations and is from a peer-reviewed journal.

5. (anderton2021theroleof pages 2-4): Meg Anderton, Emma van der Meulen, Melissa J. Blumenthal, and Georgia Schäfer. The role of the eph receptor family in tumorigenesis. Cancers, 13:206, Jan 2021. URL: https://doi.org/10.3390/cancers13020206, doi:10.3390/cancers13020206. This article has 67 citations and is from a peer-reviewed journal.

6. (arcas2020theevolutionaryhistory pages 1-2): Aida Arcas, David G Wilkinson, and M Ángela Nieto. The evolutionary history of ephs and ephrins: toward multicellular organisms. Molecular Biology and Evolution, 37:379-394, Oct 2020. URL: https://doi.org/10.1093/molbev/msz222, doi:10.1093/molbev/msz222. This article has 25 citations and is from a highest quality peer-reviewed journal.

7. (arcas2020theevolutionaryhistory pages 2-3): Aida Arcas, David G Wilkinson, and M Ángela Nieto. The evolutionary history of ephs and ephrins: toward multicellular organisms. Molecular Biology and Evolution, 37:379-394, Oct 2020. URL: https://doi.org/10.1093/molbev/msz222, doi:10.1093/molbev/msz222. This article has 25 citations and is from a highest quality peer-reviewed journal.

8. (bajaj2023crystalstructureof pages 8-11): Teena Bajaj, John Kuriyan, and Christine L. Gee. Crystal structure of the kinase domain of a receptor tyrosine kinase from a choanoflagellate, monosiga brevicollis. PLOS ONE, 18:e0276413, Jun 2023. URL: https://doi.org/10.1371/journal.pone.0276413, doi:10.1371/journal.pone.0276413. This article has 5 citations and is from a peer-reviewed journal.

9. (barquilla2015ephreceptorsand pages 17-19): Antonio Barquilla and Elena B. Pasquale. Eph receptors and ephrins: therapeutic opportunities. Annual Review of Pharmacology and Toxicology, 55:465-487, Jan 2015. URL: https://doi.org/10.1146/annurev-pharmtox-011112-140226, doi:10.1146/annurev-pharmtox-011112-140226. This article has 339 citations and is from a highest quality peer-reviewed journal.

10. (chatzikalil2024theclinicalrelevance pages 1-2): Elena Chatzikalil, Ioanna E. Stergiou, Stavros P. Papadakos, Ippokratis Konstantinidis, and Stamatios Theocharis. The clinical relevance of the eph/ephrin signaling pathway in pediatric solid and hematologic malignancies. International Journal of Molecular Sciences, 25:3834, Mar 2024. URL: https://doi.org/10.3390/ijms25073834, doi:10.3390/ijms25073834. This article has 4 citations and is from a peer-reviewed journal.

11. (chatzikalil2024theclinicalrelevance pages 2-4): Elena Chatzikalil, Ioanna E. Stergiou, Stavros P. Papadakos, Ippokratis Konstantinidis, and Stamatios Theocharis. The clinical relevance of the eph/ephrin signaling pathway in pediatric solid and hematologic malignancies. International Journal of Molecular Sciences, 25:3834, Mar 2024. URL: https://doi.org/10.3390/ijms25073834, doi:10.3390/ijms25073834. This article has 4 citations and is from a peer-reviewed journal.

12. (kwon2019tracingtheevolution pages 69-74): HA Kwon. Tracing the evolution of the tyrosine kinome from sequence to function. Unknown journal, 2019.

13. (lu2014mir137regulatesthe pages 6-6): YUCHENG LU, XUEYUAN HENG, JIXU YU, QUANPING SU, XIANGHONG GUAN, CUIPING YOU, LONG WANG, and FENGYUAN CHE. Mir-137 regulates the migration of human umbilical vein endothelial cells by targeting ephrin-type a receptor 7. Molecular medicine reports, 10 3:1475-80, Sep 2014. URL: https://doi.org/10.3892/mmr.2014.2319, doi:10.3892/mmr.2014.2319. This article has 16 citations and is from a peer-reviewed journal.

14. (vearing2005structurefunctionand pages 42-45): CJ Vearing. Structure, function and control of the epha3 receptor tyrosine kinase. Unknown journal, 2005.

15. (vearing2005structurefunctionand pages 45-48): CJ Vearing. Structure, function and control of the epha3 receptor tyrosine kinase. Unknown journal, 2005.

16. (vearing2005structurefunctionand pages 51-55): CJ Vearing. Structure, function and control of the epha3 receptor tyrosine kinase. Unknown journal, 2005.

17. (anderton2021theroleof pages 12-13): Meg Anderton, Emma van der Meulen, Melissa J. Blumenthal, and Georgia Schäfer. The role of the eph receptor family in tumorigenesis. Cancers, 13:206, Jan 2021. URL: https://doi.org/10.3390/cancers13020206, doi:10.3390/cancers13020206. This article has 67 citations and is from a peer-reviewed journal.

18. (barquilla2015ephreceptorsand pages 29-30): Antonio Barquilla and Elena B. Pasquale. Eph receptors and ephrins: therapeutic opportunities. Annual Review of Pharmacology and Toxicology, 55:465-487, Jan 2015. URL: https://doi.org/10.1146/annurev-pharmtox-011112-140226, doi:10.1146/annurev-pharmtox-011112-140226. This article has 339 citations and is from a highest quality peer-reviewed journal.

19. (chatzikalil2024theclinicalrelevance pages 22-23): Elena Chatzikalil, Ioanna E. Stergiou, Stavros P. Papadakos, Ippokratis Konstantinidis, and Stamatios Theocharis. The clinical relevance of the eph/ephrin signaling pathway in pediatric solid and hematologic malignancies. International Journal of Molecular Sciences, 25:3834, Mar 2024. URL: https://doi.org/10.3390/ijms25073834, doi:10.3390/ijms25073834. This article has 4 citations and is from a peer-reviewed journal.

20. (kim2016epha7regulatesspiral pages 18-18): Young J. Kim, Leena A. Ibrahim, Sheng‐Zhi Wang, Wei Yuan, Oleg V. Evgrafov, James A. Knowles, Kai Wang, Huizhong W. Tao, and Li I. Zhang. Epha7 regulates spiral ganglion innervation of cochlear hair cells. Developmental Neurobiology, Apr 2016. URL: https://doi.org/10.1002/dneu.22326, doi:10.1002/dneu.22326. This article has 25 citations and is from a peer-reviewed journal.

21. (lackmann2008ephaprotein pages 13-14): Martin Lackmann and Andrew W. Boyd. Eph, a protein family coming of age: more confusion, insight, or complexity? Science Signaling, 1:re2-re2, Apr 2008. URL: https://doi.org/10.1126/stke.115re2, doi:10.1126/stke.115re2. This article has 193 citations and is from a domain leading peer-reviewed journal.

22. (lackmann2008ephaprotein pages 2-3): Martin Lackmann and Andrew W. Boyd. Eph, a protein family coming of age: more confusion, insight, or complexity? Science Signaling, 1:re2-re2, Apr 2008. URL: https://doi.org/10.1126/stke.115re2, doi:10.1126/stke.115re2. This article has 193 citations and is from a domain leading peer-reviewed journal.